| Followers | 831 |
| Posts | 120081 |
| Boards Moderated | 16 |
| Alias Born | 09/05/2002 |
Friday, March 05, 2010 8:00:17 PM
Ipilimumab MoA
This diagram from yesterday’s investor presentation elaborates on
#msg-47469758 and shows the other approaches to immuno-oncology
being employed by compounds in BMY’s pipeline. (All of these except
the CD137 antagonist came from the Medarex acquisition.)
This diagram from yesterday’s investor presentation elaborates on
#msg-47469758 and shows the other approaches to immuno-oncology
being employed by compounds in BMY’s pipeline. (All of these except
the CD137 antagonist came from the Medarex acquisition.)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
